Last reviewed · How we verify
Prevention of Meningococcal Meningitis
Approved treatments
- Rifadin · Sanofi Aventis Us
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Rocephin · Generic (originally Roche)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Meningococcal Meningitis patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Meningococcal Meningitis treatment landscape brief
- Prevention of Meningococcal Meningitis treatment updates RSS
Frequently asked questions about Prevention of Meningococcal Meningitis
What drugs treat Prevention of Meningococcal Meningitis?
Tracked treatments include Rifadin, Ceftriaxon, Rocephin.
What is the treatment for Prevention of Meningococcal Meningitis?
Standard treatment for Prevention of Meningococcal Meningitis includes Rifadin, Ceftriaxon, Rocephin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Meningococcal Meningitis patent cliff · Prevention of Meningococcal Meningitis CI report
- Treatment: Rifadin · Sanofi Aventis Us
- Treatment: Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Treatment: Rocephin · Generic (originally Roche)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing